Blood Biomarkers for Brain Disorders
A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Pathology and Molecular Diagnostics".
Deadline for manuscript submissions: closed (23 December 2022) | Viewed by 2756
Special Issue Editor
Special Issue Information
Dear Colleagues,
Brain disorders are primarily diagnosed based on the clinical presentation of a broad variety of symptoms. However, the high level of comorbidity and heterogeneity of clinical manifestations in mental disorders reduces the accuracy of the diagnosis, with the consequent compromised efficacy of pharmacological treatments.
The identification of biomarkers of brain dysfunctions is essential to aid diagnosis, predict clinical outcomes, facilitate patient stratification, and approach diseases with more tailored intervention.
To overcome the limited accessibility of the brain compartment, in recent years, great effort has been made to identify measurable biological alterations in the blood that can specifically be associated to brain disturbances. The search for blood biomarkers in brain disorders focused initially on candidate body/mind interfacing biological systems such as the immune system or the hypothalamic–pituitary–adrenal axis. Recently, unbiased research approaches through omic technologies and artificial intelligence have offered unprecedented opportunities in this field. This Special Issue on “Blood Biomarkers of Brain Disease” will include original research articles and state-of-the-art reviews focusing on the discovery of molecular markers in the blood, based on proteins, metabolites, transcripts, and epigenetic modifications, that can represent valuable tools for improving the diagnosis, prevention, and prognosis of brain disorders as well as individuals’ responses to therapies.
Dr. Luisa Lo Iacono
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- blood biomarkers
- serum
- plasma
- lymphocyte
- omic technologies
- brain disorder
- patient stratification
- personalized medicine
